Bilateral Phyllodes Giant Tumor. A Case Report Analyzed by Array-CGH
Authors:
- Francesco FortarezzaFFFrancesco Fortarezza
- Federica PezzutoFPFederica Pezzuto
- Gerardo CazzatoGerardo Cazzato
- Clelia PunzoCPClelia Punzo
- Antonio D’amatiAntonio D’amati
- Teresa LettiniTLTeresa Lettini
- Mattia GentileMGMattia Gentile
- Antonia Lucia BuonadonnaABAntonia Lucia Buonadonna
- Marta MarianoMMMarta Mariano
- Angela PezzollaAPAngela Pezzolla
- Gabriella SerioGSGabriella Serio
Open Access
- 15 October 2020
- journal article
- case report
- Published by MDPI AG in Diagnostics
- Vol. 10 (10) , 825
Abstract
The breast phyllodes tumor is a biphasic tumor that accounts for less than of 1% of all breast neoplasms. It is classified as benign, borderline, or malignant, and can mimic benign masses. Some recurrent alterations have been identified. However, a precise molecular classification of these tumors has not yet been established. Herein, we describe a case of a 43-year-old woman that was admitted to the emergency room for a significant bleeding from the breast skin. A voluminous ulcerative mass of the left breast and multiple nodules with micro-calcifications on the right side were detected at a physical examination. A left total mastectomy and a nodulectomy of the right breast was performed. The histological diagnosis of the surgical specimens reported a bilateral giant phyllodes tumor, showing malignant features on the left and borderline characteristics associated with a fibroadenoma on the right. A further molecular analysis was carried out by an array-Comparative Genomic Hybridization (CGH) to characterize copy-number alterations. Many losses were detected in the malignant mass, involving several tumor suppressor genes. These findings could explain the malignant growth and the metastatic risk. In our study, genomic profiling by an array-CGH revealed a greater chromosomal instability in the borderline mass (40 total defects) than in the malignant (19 total defects) giant phyllodes tumor, reflecting the tumor heterogeneity. Should our results be confirmed with more sensitive and specific molecular tests (DNA sequencing and FISH analysis), they could allow a better selection of patients with adverse pathological features, thus optimizing and improving patient’s management.Keywords
This publication has 16 references indexed in Scilit:
- Morphologic and genetic heterogeneity in breast fibroepithelial lesions—a comprehensive mapping studyLaboratory Investigation, 2020
- A genetic mutation panel for differentiating malignant phyllodes tumour from metaplastic breast carcinomaPathology, 2017
- Fibroepithelial lesions; The WHO spectrumSeminars in Diagnostic Pathology, 2017
- Primitive squamous cell carcinoma of the breast (SCCB): case report of an uncommon variant of metaplastic carcinoma2017
- Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast CancerJournal of Clinical Oncology, 2016
- Downregulation of ZIP kinase is associated with tumor invasion, metastasis and poor prognosis in gastric cancerInternational Journal of Cancer, 2009
- Family History, Genetic Testing, and Clinical Risk Prediction: Pooled Analysis of CHEK2*1100delC in 1,828 Bilateral Breast Cancers and 7,030 ControlsCancer Epidemiology, Biomarkers & Prevention, 2009
- Somatic mutation and gain of copy number of PIK3CA in human breast cancerBreast Cancer Research, 2005
- Immunoreactivity of p53, Ki‐67, and c‐erbB‐2 in phyllodes tumors of the breast in correlation with clinical and morphologic featuresJournal of Surgical Oncology, 2002
- Relative frequency and morphology of cancers in carriers of germline TP53 mutationsOncogene, 2001